With 2023's Largest Indian IPO, Mankind Listing Watched; GPCR-Based Candidate Enters Trials

Transplant, Oncology Divisions Planned

Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

IPO Concept
Mankind's IPO Is Indian Pharma's Biggest In 2023 So Far • Source: Shutterstock

It’s not every day that a company the size of Mankind Pharma Ltd. makes a debut on Indian stock markets. With three times the operational revenue of Pfizer’s India unit, the fourth largest Indian pharmaceutical company by domestic sales is set to list on Indian stock exchanges on 8 May.

The last time a comparable pharma firm made an initial public offering (IPO) was nearly two and a half years...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip